Oruka Therapeutics: A Potential Future Psoriasis Play

2026-02-25 10:03:10 ET

Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearly psoriasis candidate is undergoing Phase 2a investigation in an ~80-patient study that management expects to yield best-in-class data for a ~$30 billion indication in 2H26. With its IL-17 A/F inhibitor ORKA-002 expected to demonstrate three times the half-life of current best-in-class Bimzelx in a healthy subject trial, the upside potential of Oruka merited a deeper dive ahead of its earnings on March 6th. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: